COO Brett Kaplan departs Climb Bio; CEO Aoife Brennan named interim PFO

Climb Bio, Inc.

Brett Kaplan, COO and principal financial officer, separated mutually on May 23, 2025.
Kaplan receives severance: 3 months base salary ($128,749.99) plus COBRA for 3 months.
CEO Aoife Brennan appointed interim principal financial officer, effective May 24, 2025, retaining CEO role.
No changes to Brennan's compensation or arrangements in connection with this appointment.
Kaplan reaffirms confidentiality, non-compete (amended to exclude CD19/APRIL drugs), and non-solicitation obligations.

item 5.02item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Brett Kaplan

Chief Operating Officer and principal financial officer

CLYM · Climb Bio, Inc.

Effective: 2025-05-23
Successor: Aoife Brennan
Filed: May 23, 2025 23:59 UTC

On May 23, 2025, Climb Bio, Inc. (the “Company”) and Brett Kaplan, M.D., its Chief Operating Officer and principal financial officer, mutually agreed that Dr. Kaplan would separate from the Company, effective May 23, 2025

Appointed (interim)

Aoife Brennan

interim principal financial officer

CLYM · Climb Bio, Inc.

Effective: 2025-05-24
Filed: May 23, 2025 23:59 UTC

On the Separation Date, the Board of Directors of the Company appointed Aoife Brennan as the Company’s interim principal financial officer, effective as of May 24, 2025.

Source: SEC EDGAR

accession 0001193125-25-125866

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.